Ajanta Pharma

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

The dividend, the company said, will be paid on or after November 20, 2025

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Looking for the best stocks to buy today? Incred Equities has released its top stock picks for June 2025, recommending 21 stocks to 'Add' across largecap, midcap, and smallcap segments

Indus Towers, Godrej Agrovet, Phoenix Mills, Ajanta Pharma and Star Health stocks dropped up to 12% in intra-day deals on Friday; here are the key levels to track on these 5 stocks.

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

The uptick comes ahead of the company's ex-dividend date tomorrow, driven by its recent dividend announcement that promises rewards for eligible shareholders

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

Ajanta Pharma stock price update: The company has fixed May 30, 2024 as the record date to determine the eligible shareholders for buyback

Ajanta Pharma on Thursday said its consolidated net profit increased 66 per cent to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets. The drugmaker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal. Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year. Revenue from operations rose to Rs 4,209 crore for FY24 as compared with Rs 3,743 crore in FY23. The company said it distributed Rs 642 crore to its shareholders in the form of dividend in FY24. The drug firm generated a cash flow of Rs 812 crore and, given this financial position, the board of directors has approved the distribution of Rs 351 crore to shareholders in the form

Ajanta Pharma Ltd on Tuesday reported a 24.71 per cent rise in consolidated net profit at Rs 195.3 crore for the second quarter ended September 30, 2023. The company had posted a consolidated net profit of Rs 156.6 crore in the same quarter last fiscal, Ajanta Pharma said in a regulatory filing. Consolidated revenue from operations was at Rs 1,028.44 crore as against Rs 938.10 crore in the year-ago period, it added. Total expenses were marginally lower at Rs 773.8 crore as compared to Rs 775.45 crore in the corresponding period a year ago, the company said. Branded generic business in India sale was at Rs 355 crore as against Rs 314 crore in the same quarter last fiscal, while the total branded generic business sales across geographies was at Rs 743 crore in Q2 as compared to Rs 711 crore in the year-ago period, up 4 per cent, it said. In the US, the generic business posted sales of Rs 237 crore as compared to Rs 185 crore in Q2 last fiscal, up 28 per cent, the company added.

In the past two months, the stock has surged 35 per cent after it reported a healthy set of numbers for June quarter

In past one week, the stock has surged 19 per cent and rallied nearly 40 per cent so far this calendar year.

As part of its growth plans, Ajanta Pharma is looking to enhance its presence across select geographies with high growth potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker stated that it intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics. "As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical presence, which promises high growth potential," Ajanta Pharma informed its shareholders. These territories offer a large branded generics pharma market size, but the company's presence still remains small, it added. "We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm said. The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa ...